Antiproliferative activity of bacterial proteins against MDA-MB-231 human breast adenocarcinoma and Hepg2 human hepatocellular carcinoma cells

4^th World Congress on Cancer Science & Therapy

October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Asvene K Sharma, Pratibha Vats and Partha Roy

Accepted Abstracts: J Cancer Sci Ther

Abstract :

Cancer is one of the most dangerous human diseases, expected to kill about 13.3 million people annually by 2030. Protein extracts of Lactobacillus sps (MTCC 4184, 9496 and 10093), Bacillus cereus (MTCC 7166, 9017 and 10202), Serratia marcence (MTCC 7641, 7298 and 7729), Shigella flexneri (MTCC 1457 and 9543) were evaluated for anticancer potential against human cancer cell lines MDA-MB-231 and Hep-G2. Inhibition of cancer cells proliferation and apoptosis was confirmed by MTT Cell Viability Assay, Fluorescent Staining, Caspase-3 activity, DNA fragmentation and cell cycle analysis by Flowcytometry. The results showed that protein extract of Lactobacillus sps (MTCC 4184), Bacillus cereus (MTCC 10202) and Shigella flexneri (MTCC 9543) inhibited both MDA-MB-231 and HepG2 cancer cell lines. Protein extract of Lactobacillus sps (MTCC 9496), Serratia marcence (MTCC 7298 and 7729) and Bacillus cereus (MTCC 7166) inhibited growth of MDA-MB-231, while no effect on HepG2 was observed. Protein extract of Lactobacillus sps (MTCC 10093), Bacillus cereus (MTCC 2763), Serratia marcence (MTCC 7641) and Shigella flexneri (MTCC1457) were none effective to any of the cell lines. The cancer cell mortality was observed from 52% to 71% + 2%. Fluorescent staining and increased Caspase 3 activity confirmed by western blotting, DNA fragmentation and detection of cell cycle arrest by Flow cytometry suggested that apoptosis was the major mechanism in inhibition of MDA-MB-231 human breast adenocarcinoma and Hep-G2 human hepatocellular carcinoma cells. The study confirms the anticancer potential of bacterial proteins which may constitute valuable candidates for development of novel anticancer drugs.

Biography :

Asvene K Sharma has completed his PhD in Molecular Biology from CCS University Meerut. He is working as Young Scientist Fellow at Department of Biotechnology, Indian Institute of Technology-Roorkee, India and is working as a Principal Investigator for his DST Young Scientist Award Research Project.